LAVALDA BEANS: Open Payments
NPI 1992587125 · WASILLA, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$737 in 28 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $290 · 2025 $737
Food & beverage: $737
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $254 |
| ABBVIE INC. | 8 | $195 |
| Neurocrine BioSciences, Inc. | 3 | $83 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Alkermes, Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, Qelbree, Auvelity, ARISTADA, REXULTI, COBENFY.
Industry payments across AK — which companies pay providers there.
